Lipitor patent upheld
The Hague – The District Court of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin – the active ingredient of Pfizer’s bestseller Lipitor – would be infringed by a competitor product from Indian generics manufacturer Ranbaxy Laboratories Ltd. The decision, which is subject to appeal, prevents Ranbaxy from launching its drug before Lipitor’s basic patent (EP 247,633) expires in November of 2011. The decisions by the Dutch court do not affect challenges to Lipitor patents pending in other countries, including in the United States. Pfizer said it will continue to aggressively defend its patents against infringement.